The list provides guidance on the development of new and necessary treatments to stop the spread of antimicrobial resistance (AMR). These include opioid agonist maintenance treatment (or OAMT) with medicines such as methadone and buprenorphine, pharmacological treatment with opioid antagonists (such as naltrexone) as well as psychosocial support. In the guidelines, WHO recommends the use of a range of treatment options for opioid dependence. Since 1977, WHO has maintained a list of essentialmedicines as a means to promote health equity around the world. At the same time, antimicrobial resistance is challenging the effectiveness of many commonly used medicines in one of the most concerning threats to global health today.
Honduras: Listado Nacional de Medicamentos Esenciales LNME 2023 (Spanish)
Working to increase access to essentialpharmaceuticals while limiting the spread of falsified products is at the heart of WHO’s global strategy on medicines. Quality-assured, safe and effective medicines, vaccines and medicaldevices are fundamental to a functioning health system. Drug dependence treatment and care in the Republic of Serbia Meeting of technical experts on public health responses to cannabis use The publication was invited by resolution 58/5 of the Commission on Narcotic Drugs entitled “Supporting the collaboration of public health and justice… WHO Drug Information provides an overview of topics relating to drug development and regulation that are of current relevance and importance, and includes the lists of proposed and recommended International Nonproprietary Names for Pharmaceutical Substances (INN).
WHO Drug Information – Volume 39, No. 3
DDDs sometimes need to be reviewed because dosages may change over time, e.g. due to the introduction of new main indications or new research making it necessary to change the DDD. Estimating prevalence of drug use in children is not possible by using crude sales data presented in DDDs owing to the variability of children’s doses. DDDs provide a fixed unit of measurement independent of price, currencies, package size and strength enabling the researcher to assess trends in drug utilization and to perform comparisons between population groups.
Drug resistance is a major challenge to prevention and treatment efforts. Such drugs are usually only given one code and this may be a problem for users in countries where other uses are predominant. Substandard and falsified medical products This second review of the world medicines situation (first published in 1988 as The WorldDrug Situation) presents the available evidence on global production,…
Good Policy and Practice in Health Education: Education sector responses to the use of alcohol, tobacco…
Target 3.5 of UN Sustainable Development Goal 3 sets out a commitment by governments to strengthen the prevention and treatment of substance abuse. Since its creation, WHO has played an important role within the UN system in addressing the world drug problem.
This Centre is located at the Norwegian Institute of Public Health (NIPH) and the main activities of the Centre are drawn up in an agreement between the WHO Headquarters and the Government of Norway. There are also international differences between PDDs, which can be up to four or five fold higher/lower. When there is a substantial discrepancy between the PDD and the DDD, it is important to take this into consideration when evaluating and interpreting drug utilization figures. The PDD will give the average daily amount of a drug that is actually prescribed.
WHO guideline on balanced national controlled medicines policies to ensure medical access and safety
Drug consumption can be expressed in cost, number of units, number of prescriptions or by the physical quantity of drugs. Building on the value of the BPPL as a global tool, tailoring the list to country and regional contexts can account for regional variations in pathogen distribution and the AMR burden. Carbapenem-resistant Pseudomonas aeruginosa (CRPA) infection moving from critical to high priority in BPPL 2024 mirrors recent reports of decreases in global resistance. Gram-negative bacteria have built-in abilities to find new ways to resist treatment and can pass along genetic material that allows other bacteria to become drug-resistant as well. The updated BPPL incorporates new evidence and expert insights to guide research and development (R&D) for new antibiotics and promote international coordination to foster innovation. AMR occurs when bacteria, viruses, fungi, and parasites no longer respond to medicines, making people sicker and increasing the risk of disease spread, illness and deaths.
Opioid overdose is easily reversed with the opioid antidote naloxone and with basic life… There is growing concern around the world about drug use and road safety. In 2013, an estimated 181.8 million people aged years… Joint UNESCO, UNODC and WHO publication on education sector responses to substance use in 2017 UNESCO (the United Nations Educational, Scientific and Cultural…
Since then there have been incredible advances in drugs for a wide range of health concerns including disease, mental health and other conditions. WHO updates guidelines on opioid dependence treatment and overdose prevention The UNGASS marked a shift in the overall drug policy discourse to highlight the public health and human rights dimensions of the world drug problem and to achieve a better balance between supply reduction and public health measures. About 296 million people aged had used psychoactive drugs in 2021 and about 39.5 million people are estimated to be affected by drug use disorders (harmful pattern of drug use or drug dependence).
Information from research institutions, medical journals and regulatory authorities:
- The PDD will give the average daily amount of a drug that is actually prescribed.
- In Hanoi, WHO’s collaboration provides a rosy picture of health
- This limits comparisons of drug consumption at an international level.
- About 296 million people aged had used psychoactive drugs in 2021 and about 39.5 million people are estimated to be affected by drug use disorders (harmful pattern of drug use or drug dependence).
In 2022, approximately 60 million people globally engaged in non-medical opioid use, including the use of drugs like heroin, morphine, codeine, fentanyl, methadone, tramadol, and other similar substances. Currently, WHO is convening a guideline development group (GDG) for update of both guidelines with an aim to improve availability and access to treatment of opioid dependence and reduce the number of deaths from opioid overdose by providing evidence-based recommendations on the psychosocially assisted pharmacological treatment and interventions on prevention and management of opioid overdose. WHO announces development of updated guidelines for the psychosocially assisted pharmacological treatment of opioid dependence and community management of opioid overdose Opioid agonist maintenance treatment (OAMT) for people with opioid dependence is proven to be safe and effective in addressing a broad range of health… Other high priority pathogens, such as antibiotic-resistant Neisseria gonorrhoeae and Enterococcus faecium, present unique public health challenges, including persistent infections and resistance to multiple antibiotics, necessitating targeted research and public health interventions. Evidence, including systematic reviews, about treatment of opioid dependence and management of opioid overdose will be presented to the GDG.
- Drug consumption can be expressed in cost, number of units, number of prescriptions or by the physical quantity of drugs.
- “Together, we can preserve the effectiveness of life-saving antimicrobial drugs and accelerate progress toward ending these epidemics.”
- These guidelines contain recommendations on the identification and management of substance use and substance use disorders for health care services which…
- WHO recommends that essential medicines, including those that are controlled, be available to all patients at all times at a price that the individual…
- For enquiries, please send an e-mail to
International Standards for Drug Use Prevention – Second Edition, 2018
WHO’s 6th Virtual cGMP Training Marathon concludes, reinforcing global manufacturing capacities Public expenditure ranges widely between nations, from under 20% of totalhealthcare costs in high-income countries to up to 66% in low-income countries. The price of medicine remains the largest impediment toaccess and the economic impact of pharmaceuticals is substantial. Access to appropriate medications is shown to have substantial impacts on community health and the related economic indicators. Universal health coverage
Tanzania making steady progress in access to essential medicines and health products as new challenges emerge Although it was not designed as a global standard, the listnow acts as a guide for the procurement and supply of medicines at the nationaland local level. Universal health coverage can only be achieved when thereis affordable access to safe, effective and quality medicines and healthproducts. Equal access and the reliable supply of medicines is anongoing goal of WHO and global health delivery systems, the achievement ofwhich is hampered by several factors.
Classification principles and challenges
The PDD can be determined from studies of prescriptions, medical or pharmacy records, and it is important to relate the PDD to the diagnosis on which the drug is used. DDDs are normally assigned based on use in adults.For medical products approved for use in children, the dose recommendations will differ based on age and body weight. The DDDs are allocated to drugs by the WHO Collaborating Centre in Oslo, working in close association with the WHO International Working Group on Drug Statistics Methodology. This limits comparisons of drug consumption at an international level.
An operational handbook accompanies the guidelines, providing practical advice for large-scale implementation. Drug Abuse Treatment Primarily aimed at health policymakers and National TB Programme (NTP) managers, they also support healthcare providers and technical organizations engaged in TB care. WHO’s work on antimicrobial resistance For example, antibiotic-resistant Mycoplasma genitalium, which is not included in the list, is an increasing concern in some parts of the world.
Today there are thousands of drugs on the market able to prevent, treat and lessen the impact of ailments that would have been fatal just a few generations ago. 1st WHO Forum on alcohol, drugs and addictive behaviours 2nd WHO Forum on alcohol, drugs and addictive behaviours These guidelines contain recommendations on the identification and management of substance use and substance use disorders for health care services which… Cannabis is globally the most commonly used psychoactive substance under international control.
Guidelines and recommendations concerning medicines, biologicals, vaccines, medical devices, herbals and related products WHO Drug Information is a quarterly journal providing an overview of topics relating to medicines development and regulation which is targeted to a wide audience of health professionals and policy makers. It is estimated that worldwide there are almost 14.8 million people who inject drugs, of whom 15.2% live with HIV and 38.8% – with hepatitis C. Production, distribution, sale or non-medical use of many psychoactive drugs is either controlled or prohibited outside legally sanctioned channels by law. Changes to the index are made annually and a cumulative list including all ATC and DDD alterations made since 1982 is available here . For drugs where the recommended dosage differs for different indications (e.g. antipsychotics) it is important that diagnosis is linked to the prescribed daily dose given.
